Hetero has launched its generic semaglutide portfolio in overseas markets even as it is awaiting regulatory approvals in India. The launch represents the beginning of a strategic, multi-year global ...

Two-time cancer survivor Sherman McDaniel may be in fragile health, but she is sticking to her vow: “I’m not going anywhere until Generic Theater has a permanent home. Until then, I will not die.” ...

MUMBAI, (IANS) – Pharma major Lupin Limited has said that it has launched Mirabegron extended-release tablets, 25 mg, in the US market, after having received approval from the Food and Drug ...

Did our AI summary help? Hetero has begun exporting generic versions of semaglutide, accelerating competition in the global market for diabetes and obesity medicines as demand for GLP‑1 therapies ...

AI Quick Read MUMBAI: A day after semaglutide lost patent protection in India, top drugmakers including Dr Reddy’s, Sun Pharma, and Zydus Lifesciences launched generic versions priced 50-90% below the ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Following its FDA approval in the summer, Tonix Pharma's fibromyalgia therapy Tonmya has been launched onto the market in the US, becoming the first new drug for the painful condition in more than 16 ...

At the heart of this debate is Section 3(d) of the Patents Act, a safeguard designed to prevent drugmakers from extending monopoly protection through trivial modifications to existing medicines.

Alkem’s semaglutide pen devices will be marketed under the brand names Semasize, Obesema, and Hepaglide. Alkem Laboratories is positioning itself to lead India’s fast-growing weight-loss drug market, ...

Multiple domestic pharmaceutical companies launched generic semaglutide on Saturday, a day after the drug's patent expired in India, with prices falling by as much as 90% from the branded version, ...